Co-Administration of Pneumococcal Vaccine with Pfizer-BioNTech COVID-19 Vaccine Found Beneficial
New York-based Pfizer Inc. today announced positive top-line results from a Phase 3 clinical study describing the safety and immunogenicity of the PREVNAR 20™ vaccine when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) or when each vaccine was given with placebo.
PREVNAR 20 contains the broadest conjugate serotype coverage and helps protect against more strains of the bacteria that cause pneumococcal pneumonia than any other conjugate vaccine available.
Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a Pfizer-BioNTech COVID-19 vaccine dose (n=190) or with placebo (n=191).
Responses to a booster dose of the Pfizer-BioNTech COVID-19 Vaccine were also similar when given with PREVNAR 20 or given with placebo (n=189).
And the safety profile of co-administering PREVNAR 20 with a booster dose of the Pfizer-BioNTech COVID-19 Vaccine generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.
"Pfizer is steadfast in its commitment to address the burden of certain respiratory diseases while raising awareness of the importance of adult immunizations," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer, in a press statement issued on January 12, 2022.
"These new safety and immunogenicity data provide further evidence supporting the potential to administer PREVNAR 20 and the Pfizer-BioNTech COVID-19 Vaccine at the same time."
At this time, no coadministration data are included in the PREVNAR 20 or Pfizer-BioNTech COVID-19 Vaccine prescribing information.
PREVNAR 20 is Pfizer's next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the thirteen serotypes already included in PREVNAR 13®.
The vaccine also contains capsular polysaccharide conjugates for seven additional serotypes that cause invasive pneumococcal disease and have been associated with high case-fatality rates, antibiotic resistance, and/or meningitis.
Pfizer has recently submitted a supplemental Biologics License Application to the U.S. FDA to include data in the PREVNAR 20 prescribing information for adults age 18 years or older regarding coadministration of PREVNAR 20 with a seasonal inactivated influenza vaccine.